Innate Pharma (IPHA) Total Non-Current Liabilities (2017 - 2025)

Innate Pharma has reported Total Non-Current Liabilities for 9 years, with the latest figure at $55.6 million in Q4 2025.

• For the quarter ending Q4 2025, Total Non-Current Liabilities fell 24.84% year-over-year to $55.6 million; the trailing twelve-month figure through Dec 2025 stood at $55.6 million (down 24.84% YoY), and the FY2025 full-year result was $55.6 million, down 24.84% from the prior year.
• Total Non-Current Liabilities for Q4 2025 stood at $55.6 million, down from $66.1 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $112.7 million in Q2 2023, with the low at $55.6 million in Q4 2025.
• Historically, Total Non-Current Liabilities has averaged $89.2 million across 5 years, with a median of $91.3 million in 2021.
• Annual changes were most pronounced in 2021 — Total Non-Current Liabilities slumped 99.75% — and 2023, when it rose 16.68%.
• Innate Pharma's Total Non-Current Liabilities stood at $91.7 million in 2021, then climbed by 15.48% to $105.9 million in 2022, then decreased by 15.02% to $90.0 million in 2023, then retreated by 17.79% to $74.0 million in 2024, then declined by 24.84% to $55.6 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $55.6 million (Q4 2025), $66.1 million (Q2 2025), and $74.0 million (Q4 2024), per Business Quant data.